GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » Market Cap

Genmab AS (CHIX:GMABC) Market Cap : kr86,651 Mil (As of Mar. 23, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Genmab AS Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genmab AS's share price for the quarter that ended in Dec. 2024 was kr1486.5. Genmab AS's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 64 Mil. Therefore, Genmab AS's market cap for the quarter that ended in Dec. 2024 was kr94,452 Mil.

Genmab AS's quarterly market cap declined from Jun. 2024 (kr112,874 Mil) to Sep. 2024 (kr102,448 Mil) and declined from Sep. 2024 (kr102,448 Mil) to Dec. 2024 (kr94,452 Mil).

Genmab AS's annual market cap declined from Dec. 2022 (kr197,325 Mil) to Dec. 2023 (kr138,826 Mil) and declined from Dec. 2023 (kr138,826 Mil) to Dec. 2024 (kr94,452 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genmab AS's Enterprise Value for Today is kr66,579 Mil.


Genmab AS Market Cap Historical Data

The historical data trend for Genmab AS's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Market Cap Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160,918.44 172,181.16 197,325.38 138,826.25 94,452.21

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 138,826.25 135,688.70 112,874.28 102,448.08 94,452.21

Competitive Comparison of Genmab AS's Market Cap

For the Biotechnology subindustry, Genmab AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Market Cap distribution charts can be found below:

* The bar in red indicates where Genmab AS's Market Cap falls into.



Genmab AS Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Genmab AS's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=kr1486.5*63.540
=kr94,452

Genmab AS's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )=Share Price (Q: Dec. 2024 )*Shares Outstanding (EOP) (Q: Dec. 2024 )
=kr1486.5*63.540
=kr94,452

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (CHIX:GMABc) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Genmab AS Market Cap Related Terms

Thank you for viewing the detailed overview of Genmab AS's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines